Brooklyn ImmunoTherapeutics, Inc.(NYSE Amex Equities : BTX)
BTX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||-0.56%||173.42||0.7%||$1039.49m|
|LLY||Eli Lilly & Co.||2.56%||262.53||1.1%||$683.11m|
|MRK||Merck & Co., Inc.||-1.24%||75.46||0.7%||$655.76m|
|BMY||Bristol-Myers Squibb Co.||-1.24%||68.45||1.0%||$576.62m|
|NRXP||NRX Pharmaceuticals, Inc.||-8.49%||14.66||0.0%||$158.90m|
|NVO||Novo Nordisk A/S||5.49%||98.24||0.1%||$101.33m|
|BHVN||Biohaven Pharmaceutical Holding Co. Ltd.||3.72%||123.20||0.0%||$87.25m|
Brooklyn ImmunoTherapeutics, Inc. is a clinical stage biopharmaceutical company that develops IRX-2, a novel hd-IL-2 based therapy, to treat patients with cancer. IRX-2 delivers hd-IL-2 and other key cytokines to restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells. In a Phase 2a clinical trial, IRX-2 demonstrated an increase in tumor infiltrating lymphocytes, which was associated with a survival benefit in patients with head and neck cancer. The company is headquartered in New York, NY.